Journal
ONCOLOGY RESEARCH
Volume 25, Issue 7, Pages 1061-1068Publisher
COGNIZANT COMMUNICATION CORP
DOI: 10.3727/096504016X14830466773541
Keywords
Ribosomal protein L34 (RPL34); Esophageal cancer; Proliferation; Invasion; PI3K/Akt pathway
Categories
Funding
- Project Funds of Overseas Training of Medical Academic and Technical Leaders in Henan Province in P.R. China [2014006]
- Youth Technology Innovation Funds of The First Affiliated Hospital of Zhengzhou University
Ask authors/readers for more resources
Ribosomal protein L34 (RPL34) belongs to the L34E family of ribosomal proteins and contains a zinc finger motif. Aberrant expression of RPL34 has been reported in several human malignancies. However, the precise role and potential underlying mechanisms of RPL34 in human esophageal cancer remain largely unknown. Thus, the objective of this study was to investigate the role of RPL34 in esophageal cancer progression. Our results showed that the expression of RPL34 at both the mRNA and protein levels was frequently upregulated in esophageal cancer cell lines. Knockdown of RPL34 efficiently inhibited esophageal cancer cell proliferation, migration, and invasion in vitro. Mechanistically, knockdown of RPL34 significantly downregulated the protein expression level of p-PI3K and p-Akt in esophageal cancer cells. Finally, knockdown of RPL34 attenuated tumor growth in nude mice. In conclusion, our study revealed that RPL34 functions as an oncogene that modulates the proliferation and metastasis of esophageal cancer cells, in part, by the inactivation of the PI3K/Akt signaling pathway. Thus, these findings suggest that RPL34 may serve as a potential therapeutic target for the treatment of esophageal cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available